BRPI1011875A2 - compostos n-fenil-(piperazinil ou homopiperazinil)-benzenosulfonamida ou benzenosulfonil-fenil-(piperazina ou homopiperazina) adequados para tratamento de distúrbios que respondem à modulação do receptor 5-ht6 de serotonina - Google Patents
compostos n-fenil-(piperazinil ou homopiperazinil)-benzenosulfonamida ou benzenosulfonil-fenil-(piperazina ou homopiperazina) adequados para tratamento de distúrbios que respondem à modulação do receptor 5-ht6 de serotoninaInfo
- Publication number
- BRPI1011875A2 BRPI1011875A2 BRPI1011875A BRPI1011875A BRPI1011875A2 BR PI1011875 A2 BRPI1011875 A2 BR PI1011875A2 BR PI1011875 A BRPI1011875 A BR PI1011875A BR PI1011875 A BRPI1011875 A BR PI1011875A BR PI1011875 A2 BRPI1011875 A2 BR PI1011875A2
- Authority
- BR
- Brazil
- Prior art keywords
- phenyl
- homopiperazine
- homopiperazinyl
- benzenesulfonamide
- benzenesulfonyl
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 2
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 150000004050 homopiperazines Chemical class 0.000 title 1
- -1 homopiperazinyl Chemical group 0.000 title 1
- 125000004193 piperazinyl group Chemical group 0.000 title 1
- 229940076279 serotonin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17405409P | 2009-04-30 | 2009-04-30 | |
| PCT/EP2010/055789 WO2010125134A1 (en) | 2009-04-30 | 2010-04-29 | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011875A2 true BRPI1011875A2 (pt) | 2018-06-19 |
Family
ID=42236832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011875A BRPI1011875A2 (pt) | 2009-04-30 | 2010-04-29 | compostos n-fenil-(piperazinil ou homopiperazinil)-benzenosulfonamida ou benzenosulfonil-fenil-(piperazina ou homopiperazina) adequados para tratamento de distúrbios que respondem à modulação do receptor 5-ht6 de serotonina |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8076326B2 (pt) |
| EP (1) | EP2432769B1 (pt) |
| JP (1) | JP5718898B2 (pt) |
| KR (1) | KR20120016639A (pt) |
| CN (1) | CN102459197B (pt) |
| AR (1) | AR076507A1 (pt) |
| AU (1) | AU2010243585B2 (pt) |
| BR (1) | BRPI1011875A2 (pt) |
| CA (1) | CA2759482A1 (pt) |
| CL (1) | CL2011002653A1 (pt) |
| CO (1) | CO6450637A2 (pt) |
| CR (1) | CR20110604A (pt) |
| DO (1) | DOP2011000326A (pt) |
| EC (1) | ECSP11011468A (pt) |
| ES (1) | ES2536779T3 (pt) |
| IL (1) | IL215642A (pt) |
| MX (1) | MX2011011520A (pt) |
| NZ (1) | NZ595698A (pt) |
| PE (1) | PE20120881A1 (pt) |
| RU (1) | RU2535200C2 (pt) |
| SG (1) | SG175187A1 (pt) |
| TW (1) | TWI465438B (pt) |
| UA (1) | UA107080C2 (pt) |
| UY (1) | UY32604A (pt) |
| WO (1) | WO2010125134A1 (pt) |
| ZA (1) | ZA201107569B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2300437B1 (en) | 2008-06-05 | 2013-11-20 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
| JP5502077B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規な化合物 |
| EP2280705B1 (en) | 2008-06-05 | 2014-10-08 | Glaxo Group Limited | Novel compounds |
| EP2406255B1 (en) | 2009-03-09 | 2015-04-29 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases |
| US8343959B2 (en) * | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
| AR076435A1 (es) | 2009-04-30 | 2011-06-08 | Glaxo Group Ltd | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| WO2012059432A1 (en) * | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
| US20140120036A1 (en) * | 2012-01-06 | 2014-05-01 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
| WO2014090712A1 (en) * | 2012-12-10 | 2014-06-19 | F. Hoffmann-La Roche Ag | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS |
| BR112015023571A2 (pt) * | 2013-03-15 | 2017-07-18 | Hoffmann La Roche | derivados de sulfamato e sulfamida de arila como moduladores rorc |
| WO2015090233A1 (en) | 2013-12-20 | 2015-06-25 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| CN105085436B (zh) * | 2014-04-19 | 2019-08-16 | 广东东阳光药业有限公司 | 磺酰胺类衍生物及其在药物上的应用 |
| WO2023067550A1 (en) * | 2021-10-20 | 2023-04-27 | Yousef Najajreh | Allosteric inhibitor compounds for overcoming cancer resistance |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| HUP0003073A3 (en) * | 1997-07-11 | 2002-10-28 | Smithkline Beecham Plc | Benzenesulfonamide derivatives, process for producing them and their use as medicines |
| GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| GB9818914D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| SE0002739D0 (sv) | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New use |
| CN1329382C (zh) | 2001-05-11 | 2007-08-01 | 比奥维特罗姆股份公司 | 治疗肥胖、ⅱ型糖尿病和cns－疾病的芳基磺酰胺化合物 |
| KR100889718B1 (ko) * | 2001-06-11 | 2009-03-23 | 바이오비트럼 에이비(피유비엘) | 치환 술폰아미드 화합물, ｃｎｓ 장애, 비만 및 ⅱ 형당뇨병 치료용 약제로서의 이들의 사용 방법 |
| CA2456250A1 (en) * | 2001-08-10 | 2003-02-20 | F. Hoffmann-La Roche Ag | Arylsulfonyl derivatives with 5-ht6 receptor affinity |
| JP4467307B2 (ja) * | 2002-02-22 | 2010-05-26 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ５−ｈｔ受容体アンタゴニストとしてのピリジルスルホン誘導体 |
| GB0305575D0 (en) | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| AU2005266448A1 (en) | 2004-07-28 | 2006-02-02 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
| GB0419192D0 (en) * | 2004-08-27 | 2004-09-29 | Merck Sharp & Dohme | Therapeutic agents |
| EP1999121A1 (en) * | 2006-03-17 | 2008-12-10 | AstraZeneca AB | Novel tetralins as 5-ht6 modulators |
| WO2007118899A1 (en) * | 2006-04-19 | 2007-10-25 | Abbott Gmbh & Co. Kg | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor |
| WO2008087123A2 (en) | 2007-01-16 | 2008-07-24 | Solvay Pharmaceuticals B.V. | Use of 5-ht6 antagonists to prevent relapse into addiction |
-
2010
- 2010-04-29 UA UAA201114123A patent/UA107080C2/ru unknown
- 2010-04-29 KR KR1020117028393A patent/KR20120016639A/ko not_active Ceased
- 2010-04-29 ES ES10719748.5T patent/ES2536779T3/es active Active
- 2010-04-29 CN CN201080030335.8A patent/CN102459197B/zh not_active Expired - Fee Related
- 2010-04-29 JP JP2012507761A patent/JP5718898B2/ja not_active Expired - Fee Related
- 2010-04-29 NZ NZ595698A patent/NZ595698A/en not_active IP Right Cessation
- 2010-04-29 MX MX2011011520A patent/MX2011011520A/es active IP Right Grant
- 2010-04-29 BR BRPI1011875A patent/BRPI1011875A2/pt not_active IP Right Cessation
- 2010-04-29 AU AU2010243585A patent/AU2010243585B2/en not_active Ceased
- 2010-04-29 CA CA2759482A patent/CA2759482A1/en not_active Abandoned
- 2010-04-29 EP EP10719748.5A patent/EP2432769B1/en active Active
- 2010-04-29 SG SG2011074325A patent/SG175187A1/en unknown
- 2010-04-29 RU RU2011148583/04A patent/RU2535200C2/ru not_active IP Right Cessation
- 2010-04-29 WO PCT/EP2010/055789 patent/WO2010125134A1/en not_active Ceased
- 2010-04-29 PE PE2011001879A patent/PE20120881A1/es not_active Application Discontinuation
- 2010-04-30 TW TW099113996A patent/TWI465438B/zh not_active IP Right Cessation
- 2010-04-30 US US12/770,837 patent/US8076326B2/en not_active Expired - Fee Related
- 2010-04-30 AR ARP100101465A patent/AR076507A1/es not_active Application Discontinuation
- 2010-04-30 UY UY0001032604A patent/UY32604A/es not_active Application Discontinuation
-
2011
- 2011-10-09 IL IL215642A patent/IL215642A/en not_active IP Right Cessation
- 2011-10-14 ZA ZA2011/07569A patent/ZA201107569B/en unknown
- 2011-10-25 CL CL2011002653A patent/CL2011002653A1/es unknown
- 2011-10-25 DO DO2011000326A patent/DOP2011000326A/es unknown
- 2011-11-03 CO CO11149288A patent/CO6450637A2/es active IP Right Grant
- 2011-11-15 CR CR20110604A patent/CR20110604A/es unknown
- 2011-11-21 EC EC2011011468A patent/ECSP11011468A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201107569B (en) | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| BRPI0812853A2 (pt) | Compostos de quinolina adequados para tratar distúrbios que respondem à modulação do receptor 5-ht6 de serotonina. | |
| CL2013000380A1 (es) | Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion. | |
| CO7000771A2 (es) | Proceso para la fabricación de 1-[2-(2,4-dimetilsulfanil)fenil]piperazina | |
| BRPI0918527A2 (pt) | compostos para o tratamento de disturbios do cns | |
| ECSP088961A (es) | Nuevos herbicidas | |
| CO7091184A2 (es) | Agentes para tratar trastornos que implican la modulación de receptores de riandonina | |
| BRPI0814180A2 (pt) | Método para reduzir os sintomas de, ou para tratar, um ou mais distúrbios nos quais o sistema dopaminérgico está desregulado | |
| BR112013031551A2 (pt) | aparelhos de lâmpada de descarga de ultravioleta com um ou mais refletores e sistemas os quais determinam os parâmetros de operação e as programações de desinfecção para dispositivos germicidas. | |
| EP2809322A4 (en) | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| BRPI1013777A2 (pt) | compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos. | |
| PT2838539T (pt) | Derivados estrogénicos para utilização no tratamento de distúrbios neurológicos. | |
| PT2627345E (pt) | Formulações para o tratamento de distúrbios das vias respiratórias superiores | |
| IL201107A0 (en) | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| CL2014000852A1 (es) | Proteína de fusión que comprende dominio extracelular de la proteina humana del receptor humano notch1; composicion que la comprende. | |
| BRPI0809081A2 (pt) | compostos de quinolina adequados para tratamento de distúrbios que respondem á modulação do receptor da serotonina 5-ht6 | |
| EP3390369A4 (en) | SOLID FORMS OF SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO [F] ISOQUINOLIN-2-AMINE COMPOUNDS | |
| BRPI0816142A2 (pt) | Modulador de nrg1 para tratamento de distúrbios respiratórios. | |
| BRPI0819233A2 (pt) | compostos de benzenossulfonanilida adequadas para tratar distúrbios que respondem à modulação do receptor 5-ht6 de serotonina | |
| BR112017024745A2 (pt) | compostos e métodos para modulação de receptores de serotonina na periferia. | |
| BRPI0923862A2 (pt) | Compostos sulfonamida para o tratamento de distúrbios respiratórios | |
| EP3334428A4 (en) | COMPOSITIONS WITH S1P RECEPTOR MODULATORS | |
| BR112012004988A2 (pt) | compostos para tratar transtornos ou doenças associadas com atividade do receptor de neuroquinina 2 | |
| ES1073254Y (es) | Electrovalvula para la regulacion de fluidos | |
| ES1176384Y (es) | Sistema para la gestión integral de desechos domésticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2477 DE 26-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B25B | Requested transfer of rights rejected |
Owner name: ABBOTT GMBH AND CO. KG (DE) ; ABBOTT LABORATORIES Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 860140107624 DE 01/07/2014EM VIRTUDE DO DESPACHO PUBLICADO NA RPI NO 2494 DE 23/10/2018. |